On Apr 17, 2018 Acorda Therapeutics Inc (NASDAQ:ACOR) Sellers Rose Their Shorts By 1.34%

April 17, 2018 - By Robert Reynolds

Acorda Therapeutics, Inc. (NASDAQ:ACOR) Corporate Logo

Big Money Sentiment decreased to 0.99 in 2017 Q4. It has change of 0.23, from 2017Q3’s 1.22. The ratio is negative due to Acorda Therapeutics, Inc. positioning: 24 sold and 46 reduced. 23 funds acquired positions and 46 increased positions. Investors holded 51.31 million in 2017Q3 but now own 48.17 million shares or 6.13% less.
Tower Rech Cap Limited Liability Company (Trc) holds 0% of its capital in Acorda Therapeutics, Inc. (NASDAQ:ACOR) for 1,416 shs. Whittier Trust, California-based fund reported 250 shs. Northern Trust holds 0.01% or 1.04M shs. Ny State Teachers Retirement Sys holds 59,236 shs. Voya Investment Management Limited Company has 39,380 shs. Manufacturers Life Insur The reported 33,230 shs. Riverhead Cap Mgmt Ltd Limited Liability Company, Delaware-based fund reported 5,587 shs. Great West Life Assurance Can reported 60,160 shs. Moreover, State Of Tennessee Treasury Department has 0% invested in Acorda Therapeutics, Inc. (NASDAQ:ACOR) for 36,496 shs. Matarin Mgmt Ltd Liability Co owns 90,767 shs. Blackrock stated it has 0.01% in Acorda Therapeutics, Inc. (NASDAQ:ACOR). Sector Pension Inv Board owns 0.01% invested in Acorda Therapeutics, Inc. (NASDAQ:ACOR) for 60,695 shs. Strs Ohio holds 0% of its capital in Acorda Therapeutics, Inc. (NASDAQ:ACOR) for 41,300 shs. 240,388 were reported by Prudential Fin. Moreover, Tci Wealth Advsr has 0% invested in Acorda Therapeutics, Inc. (NASDAQ:ACOR).

Acorda Therapeutics, Inc. had 2 sales and 0 insider purchases since January 18, 2018. This’s net activity of $1.81 million. 31,000 shs were sold by LAWRENCE DAVID, worth $854,911.

Acorda Therapeutics Inc (NASDAQ:ACOR) noted an increase of 1.34% in shorted shares. It was announced in April by FINRA the 6.27 million shorted shares on ACOR. The up change of 1.34% from 6.19M shares was reported. Previous ACOR’s position will need 14 days to restore. It has 449,800 average volume. Acorda Therapeutics Inc’s shorted shares float is 18.82%.

$23.35 was the last price.Since April 17, 2017 it’s 10.61% down thus downtrending. ACOR underperformed by 22.16% the S&P 500.

Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States.The firm is valued at $1.10 billion. The firm markets Ampyra , an oral drug to improve walking in patients with multiple sclerosis (MS); Zanaflex capsules and tablets for the management of spasticity; and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia.Currently it has negative earnings. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas.

Acorda Therapeutics, Inc. (NASDAQ:ACOR) Ratings Coverage

In total 10 analysts cover Acorda Therapeutics (NASDAQ:ACOR). “Buy” rating has 3, “Sell” are 1, while 6 are “Hold”. 30% are bullish. With $35 highest and $16.0 lowest [Target] Acorda Therapeutics has $24.57 average [Target] or 5.22% above the current ($23.35) price. 20 are the (NASDAQ:ACOR)’s analyst reports since October 31, 2017 according to StockzIntelligence Inc. On Wednesday, November 15 the stock of Acorda Therapeutics, Inc. (NASDAQ:ACOR) has “Buy” rating given by Cowen & Co. On Wednesday, November 1 the rating was maintained by Jefferies with “Hold”. In Wednesday, January 17 report H.C. Wainwright maintained the stock with “Buy” rating. On Wednesday, February 7 the company was upgraded by Goldman Sachs. In Thursday, December 14 report H.C. Wainwright maintained it with “Buy” rating and $34.0 target. On Tuesday, November 28 Piper Jaffray initiated Acorda Therapeutics, Inc. (NASDAQ:ACOR) with “Hold” rating. On Wednesday, November 15 Jefferies maintained the shares of ACOR in report with “Hold” rating. On Thursday, November 16 the firm has “Underperform” rating given by Raymond James. On Thursday, February 15 the firm has “Buy” rating given by Piper Jaffray. In Tuesday, October 31 report Cantor Fitzgerald maintained it with “Hold” rating and $18.0 target.

Acorda Therapeutics, Inc. (NASDAQ:ACOR) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: